[go: up one dir, main page]

WO2000049410A3 - Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules - Google Patents

Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules Download PDF

Info

Publication number
WO2000049410A3
WO2000049410A3 PCT/US2000/004023 US0004023W WO0049410A3 WO 2000049410 A3 WO2000049410 A3 WO 2000049410A3 US 0004023 W US0004023 W US 0004023W WO 0049410 A3 WO0049410 A3 WO 0049410A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
protein
analysis
methods
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004023
Other languages
English (en)
Other versions
WO2000049410A2 (fr
WO2000049410A9 (fr
Inventor
Lance A Liotta
Nicole Simone
Michael Emmert-Buck
Emmanuel F Petricoin Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
US Department of Health and Human Services
Original Assignee
National Institutes of Health NIH
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, US Department of Health and Human Services filed Critical National Institutes of Health NIH
Priority to US09/913,667 priority Critical patent/US6969614B1/en
Priority to CA002359649A priority patent/CA2359649A1/fr
Priority to EP00911845A priority patent/EP1153300A2/fr
Priority to JP2000600101A priority patent/JP2002537561A/ja
Priority to AU33671/00A priority patent/AU772680B2/en
Publication of WO2000049410A2 publication Critical patent/WO2000049410A2/fr
Publication of WO2000049410A3 publication Critical patent/WO2000049410A3/fr
Anticipated expiration legal-status Critical
Publication of WO2000049410A9 publication Critical patent/WO2000049410A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/2813—Producing thin layers of samples on a substrate, e.g. smearing, spinning-on
    • G01N2001/2833—Collecting samples on a sticky, tacky, adhesive surface
    • G01N2001/284—Collecting samples on a sticky, tacky, adhesive surface using local activation of adhesive, i.e. Laser Capture Microdissection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La présente invention concerne des dispositifs et des procédés d'analyse protéique de cellules ayant subi une microdissection par capture au laser, permettant l'analyse protéomique de cellules provenant de populations variées. Des exemples particuliers de cette invention se rapportent à l'analyse de cellules normales par rapport aux cellules malignes, ou à la comparaison de l'expression protéique différentielle dans des cellules évoluant de l'état normal à l'état malin. La teneur protéique des cellules microdisséquées peut être analysée avec des techniques comme le dosage immunologique, la caractérisation par électrophorèse unidimensionnelle et bidimensionnelle en gélose, le 'Western blotting', l'électronébulisation à piégeage d'ions quadrupôles par chromatographie liquide (LCQ-MS), la désorption-ionisation par impact laser assistée par matrice/ temps de vol (MALDI/TV), la spectroscopie à ionisation/désorption avec exaltation de surface (SELDI). Par ailleurs, en plus de permettre la comparaison directe entre la teneur qualitative et quantitative protéique des cellules tumorales et normales provenant d'un même prélèvement tissulaire, ces procédés permettent également la recherche des caractéristiques protéiques des cellules tumorales, comme par exemple la capacité de liaison et la séquence d'acide aminé, et l'expression différentiée des protéines dans des populations de cellules particulières en réponse à un traitement par des médicaments. Grâce aux empreintes protéiques, ces procédés constituent un moyen efficace et rapide d'identification du tissu responsable de métastases.
PCT/US2000/004023 1999-02-16 2000-02-16 Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules Ceased WO2000049410A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/913,667 US6969614B1 (en) 1999-02-16 2000-02-16 Methods for the isolation and analysis of cellular protein content
CA002359649A CA2359649A1 (fr) 1999-02-16 2000-02-16 Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules
EP00911845A EP1153300A2 (fr) 1999-02-16 2000-02-16 Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules
JP2000600101A JP2002537561A (ja) 1999-02-16 2000-02-16 細胞タンパク質成分を単離および分析するための方法および装置
AU33671/00A AU772680B2 (en) 1999-02-16 2000-02-16 LCM (Laser capture microdissection) for cellular protein analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12028899P 1999-02-16 1999-02-16
US60/120,288 1999-02-16

Publications (3)

Publication Number Publication Date
WO2000049410A2 WO2000049410A2 (fr) 2000-08-24
WO2000049410A3 true WO2000049410A3 (fr) 2001-03-08
WO2000049410A9 WO2000049410A9 (fr) 2001-08-30

Family

ID=22389357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004023 Ceased WO2000049410A2 (fr) 1999-02-16 2000-02-16 Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules

Country Status (5)

Country Link
EP (1) EP1153300A2 (fr)
JP (1) JP2002537561A (fr)
AU (1) AU772680B2 (fr)
CA (1) CA2359649A1 (fr)
WO (1) WO2000049410A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7075640B2 (en) 1997-10-01 2006-07-11 Arcturus Bioscience, Inc. Consumable for laser capture microdissection
US7676328B2 (en) 2000-09-04 2010-03-09 Mpb Meltec Patent-Und Beteiligungsgesellschaft Mbh Method for identifying cell-specific proteins
US7761239B2 (en) 2003-12-11 2010-07-20 Correlogic Systems, Inc. Method of diagnosing biological states through the use of a centralized, adaptive model, and remote sample processing
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7069151B2 (en) * 2000-02-08 2006-06-27 Regents Of The University Of Michigan Mapping of differential display of proteins
JP2003532055A (ja) * 2000-03-20 2003-10-28 イースタン バージニア メディカル スクール 前立腺癌マーカー
US7096206B2 (en) 2000-06-19 2006-08-22 Correlogic Systems, Inc. Heuristic method of classification
BR0112667A (pt) 2000-07-18 2006-05-09 Correlogic Systems Inc processo de distinção entre estados biológicos baseados em padrões ocultos de dados biológicos
US20020132260A1 (en) * 2001-02-22 2002-09-19 Erlander Mark G. Quantitative immunohistochemistry (QIHC)
US6677303B2 (en) 2001-04-30 2004-01-13 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US6998243B2 (en) * 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US20020160421A1 (en) * 2001-04-30 2002-10-31 George Jackowski Method for monitoring and validating stress induction of disease state
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US6620786B2 (en) * 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
US20020160423A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons
US6627608B2 (en) * 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
US7049397B2 (en) 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US7087435B2 (en) * 2001-04-30 2006-08-08 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
US20020160533A1 (en) 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons
US20030040602A1 (en) * 2001-04-30 2003-02-27 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons
US6599877B2 (en) 2001-04-30 2003-07-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
US7008800B2 (en) 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US6703366B2 (en) 2001-04-30 2004-03-09 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons
US6693080B2 (en) 2001-04-30 2004-02-17 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons
US20020160417A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
US20040198950A1 (en) * 2001-04-30 2004-10-07 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US20020160434A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons
US20020160418A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1949 daltons
US20020160532A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
US6602855B2 (en) * 2001-04-30 2003-08-05 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US20040224423A1 (en) * 2001-04-30 2004-11-11 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US6593298B2 (en) * 2001-04-30 2003-07-15 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6890763B2 (en) * 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US6620787B2 (en) 2001-04-30 2003-09-16 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
US6627607B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US6627606B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
US7314762B2 (en) 2001-11-21 2008-01-01 Nanogen, Inc. Apolipoprotein biopolymer markers indicative of insulin resistance
AU2002336845A1 (en) * 2001-11-23 2003-06-10 Syn.X Pharma, Inc. Globin biopolymer markers indicative of insulin resistance
US7125678B2 (en) 2001-11-23 2006-10-24 Nanogen, Inc. Protein biopolymer markers predictive of type II diabetes
US7097989B2 (en) * 2001-11-23 2006-08-29 Syn X Pharma, Inc. Complement C3 precursor biopolymer markers predictive of type II diabetes
US20070003974A1 (en) * 2001-11-23 2007-01-04 George Jackowski Cene-E biopolymer marker indicative of age matched control
US20090093000A1 (en) * 2001-11-23 2009-04-09 George Jackowski Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
AR040711A1 (es) 2002-07-29 2005-04-13 Us Agriculture Un metodo para verificacion de calidad/control de calidad para proceso de bioensayo de alto rendimiento
SE0202346D0 (sv) * 2002-07-30 2002-07-30 Astrazeneca Ab Profiling process
US7695752B2 (en) 2003-01-24 2010-04-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
US7709047B2 (en) 2003-01-24 2010-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
US8962302B2 (en) 2005-11-07 2015-02-24 Canon Kabushiki Kaisha Biological tissue processing substrate for fixing proteins or protein degradation products in tissue for analysis
EP2071313A4 (fr) * 2006-09-28 2012-10-31 Shimadzu Corp Procédé de déparaffinage d'un échantillon noyé dans de la paraffine et procédé d'analyse d'un échantillon noyé dans de la paraffine
US9502227B2 (en) 2007-11-02 2016-11-22 Humanix Co., Ltd. Capturing of cell fluid and analysis of its components under observation of cells and instruments for the cell fluid capturing and the analysis
EP2863226A1 (fr) 2007-11-02 2015-04-22 Humanix Co., Ltd. Procédé de capture d'un fluide et d'analyse de composants de celui-ci et système pour capturer et analyser un fluide
EP2309262A1 (fr) * 2009-10-06 2011-04-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé pour la quantification de biomolécules
CN102621301B (zh) * 2011-01-28 2014-10-08 上海铭源数康生物芯片有限公司 一种基于硝酸纤维素膜的蛋白芯片封闭液的制备方法
WO2015199976A1 (fr) 2014-06-24 2015-12-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Microdissection activée par une cible
CN106644632B (zh) * 2016-11-17 2019-08-27 中国科学院苏州生物医学工程技术研究所 用于单层细胞平铺的人工基质
CN113740544A (zh) * 2021-07-29 2021-12-03 山东第一医科大学(山东省医学科学院) 鉴定人垂体组织泌乳激素蛋白质存在形式生物标志物方法
WO2023250212A1 (fr) * 2022-06-24 2023-12-28 The Johns Hopkins Univeristy Systèmes de microdissection d'expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61275221A (ja) * 1985-05-30 1986-12-05 Mitsui Pharmaceut Inc タンパク質
US4976957A (en) * 1974-03-12 1990-12-11 Samuel Bogoch Process for the production of recognins and their chemoreciprocals
US5843657A (en) * 1994-03-01 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Isolation of cellular material under microscopic visualization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4976957A (en) * 1974-03-12 1990-12-11 Samuel Bogoch Process for the production of recognins and their chemoreciprocals
JPS61275221A (ja) * 1985-05-30 1986-12-05 Mitsui Pharmaceut Inc タンパク質
US5843657A (en) * 1994-03-01 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Isolation of cellular material under microscopic visualization

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BANKS ROSAMONDE E; DUNN MICHAEL J ET AL.: "The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - Preliminary findings", ELECTROPHORESIS, vol. 20, April 1999 (1999-04-01) - May 1999 (1999-05-01), pages 689 - 700, XP000925546 *
CAZARES L H; GONG L; NASIM S; SCHELLMAMMER P F; WRIGHT G L JR: "Discovery of prostate cancer biomarkers from laser capture microdissected (LCM) cells using innovative ProteinChipTM SELDI mass spectroscopy", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (91ST ANNUAL MEETING, SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000), March 2000 (2000-03-01), pages 851, XP000929268 *
DATABASE WPI Week 198703, Derwent World Patents Index; AN 1987-017788, XP002143852, NOGUCHI JUJI ET AL.: "Protein from animal cerebral nerve tumour cell ..." *
EMMERT-BUCK M R; ORNSTEIN D K; GILLESPIE J W; PAWELETZ C P; VOCKE C D; ET AL.: "Protein fingerprinting of LCM-dissected human esophageal and prostate cancer by 2D-PAGE", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, no. 526, March 1999 (1999-03-01), pages 526, XP000929253 *
EMMERT-BUCK MICHAEL R; GILLESPIE JOHN W ET AL.: "An approach to proteomic analysis of human tumors", MOLECULAR CARCINOGENESIS, vol. 27, March 2000 (2000-03-01), pages 158 - 165, XP000925515 *
SIMONE N L ET AL: "Laser-capture microdissection: opening the microscopic frontier to molecular analysis", TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 14, no. 7, 1 July 1998 (1998-07-01), pages 272 - 276, XP004124689, ISSN: 0168-9525 *
SIMONE N L; REMALEY A T; PETRICOIN E F; GLICKMAN J W; BONNER R; EMMERT-BUCK M R; FLEISCHER T A; LIOTTA L A: "PSA quantitation in prostate cancer tissue cells procured by laser capture microdissection", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING (90TH ANNUAL MEETING, PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999), vol. 40, March 1999 (1999-03-01), pages 411, XP000929252 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7075640B2 (en) 1997-10-01 2006-07-11 Arcturus Bioscience, Inc. Consumable for laser capture microdissection
US7221447B2 (en) 1997-10-01 2007-05-22 Molecular Devices Corporation Consumable for laser capture microdissection
US7676328B2 (en) 2000-09-04 2010-03-09 Mpb Meltec Patent-Und Beteiligungsgesellschaft Mbh Method for identifying cell-specific proteins
US7761239B2 (en) 2003-12-11 2010-07-20 Correlogic Systems, Inc. Method of diagnosing biological states through the use of a centralized, adaptive model, and remote sample processing
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
US9274118B2 (en) 2007-06-29 2016-03-01 Vermillion, Inc. Predictive markers for ovarian cancer

Also Published As

Publication number Publication date
WO2000049410A2 (fr) 2000-08-24
JP2002537561A (ja) 2002-11-05
EP1153300A2 (fr) 2001-11-14
CA2359649A1 (fr) 2000-08-24
WO2000049410A9 (fr) 2001-08-30
AU3367100A (en) 2000-09-04
AU772680B2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2000049410A3 (fr) Procedes et dispositifs d'isolation et d'analyse de la teneur proteique des cellules
Chaurand et al. Profiling proteins from azoxymethane‐induced colon tumors at the molecular level by matrix‐assisted laser desorption/ionization mass spectrometry
Shen et al. Capillary zone electrophoresis-mass spectrometry for top-down proteomics
Takemori et al. PEPPI-MS: polyacrylamide-gel-based prefractionation for analysis of intact proteoforms and protein complexes by mass spectrometry
Stutz Advances in the analysis of proteins and peptides by capillary electrophoresis with matrix‐assisted laser desorption/ionization and electrospray‐mass spectrometry detection
Fuchs et al. An update of MALDI-TOF mass spectrometry in lipid research
US7425700B2 (en) Systems and methods for discovery and analysis of markers
Liu et al. On-line dual microdialysis with ESI-MS for direct analysis of complex biological samples and microorganism lysates
US11199547B2 (en) Methods and systems for LC-MS/MS proteomic genotyping
WO2004042072A3 (fr) Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice
WO2008005455A3 (fr) Déplétion des peptides par anticorps et son application à la préparation des échantillons pour spectrométrie de masse
Rejtar et al. Increased identification of peptides by enhanced data processing of high-resolution MALDI TOF/TOF mass spectra prior to database searching
WO2005123959A3 (fr) Detection d'analysat par essais a multiplexage
Pashkova et al. Coumarin tags for analysis of peptides by MALDI-TOF MS and MS/MS. 2. Alexa Fluor 350 tag for increased peptide and protein identification by LC-MALDI-TOF/TOF MS
WO2004050845A3 (fr) Methodes de quantification et d'identification de peptides et de proteines
O’Neil et al. Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis
Hughes et al. Laser capture microdissection and native mass spectrometry for spatially-resolved analysis of intact protein assemblies in tissue
US12352768B2 (en) Automatic sample workflow for LC-MS based HbA1c measurement on intact protein level
Chen et al. Rapid identification and screening of proteins from whole cell lysates of human erythroleukemia cells in the liquid phase, using non‐porous reversed phase high‐performance liquid chromatography separations of proteins followed by multi‐assisted laser desorption/ionization mass spectrometry analysis and sequence database searching
Chen et al. Device for the reversed-phase separation and on-target deposition of peptides incorporating a hydrophobic sample barrier for matrix-assisted laser desorption/ionization mass spectrometry
Zhu et al. Use of two-dimensional liquid fractionation for separation of proteins from cell lysates without the presence of methionine oxidation
WO2006062471B1 (fr) Procedes et interfaces de separations simples et multidimensionnelles, aux fins de caracterisation et/ou d'identification de molecules par spectrometrie de masse
Zhang et al. Membrane-assisted capillary isoelectric focusing coupling with matrix-assisted laser desorption/ionization-Fourier transform mass spectrometry for neuropeptide analysis
Nie et al. Coupling microchip electrophoresis with MALDI-TOF-MS based on a freezing technique
Vishwakarma et al. Analysis of intact venom proteins with capillary zone electrophoresis-mass spectrometry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 33671/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2359649

Country of ref document: CA

Ref country code: CA

Ref document number: 2359649

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 600101

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/22-22/22, DRAWINGS, REPLACED BY NEW PAGES 1/22-22/22

WWE Wipo information: entry into national phase

Ref document number: 2000911845

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000911845

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09913667

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 33671/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000911845

Country of ref document: EP